Clinical Trial Update: Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients [Phase 3]

View source ↗

Summary

This Phase 3 trial update assesses the safety and tolerability of Omalizumab in adults with poorly controlled moderate-to-severe asthma and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 3 | Status: COMPLETED